Pasi Huttunen
Research Subjects
Pasi Huttunen has a total of 66 co-authors. Here are the top co-authors by number of shared publications:
- Mervi Taskinen
Hospital for Children and Adolescents, University of Helsinki, Helsinki, Finland
3 shared publications - Adam Alexandersson
Division of Hematology-Oncology and Stem Cell Transplantation, Children’s Hospital, Helsinki University Hospital, University of Helsinki, Helsinki, Finland
2 shared publications - Eliisa Kekäläinen
Translational Immunology Research Program University of Helsinki and Helsinki University Hospital Helsinki Finland
2 shared publications - Laura L. Elo
Turku Bioscience Centre, University of Turku and Åbo Akademi University, Turku, Finland
2 shared publications Mervi Taskinen
Division of Hematology-Oncology and Stem Cell Transplantation, New Children´s Hospital, Helsinki University Hospital and University of Helsinki, Helsinki, Finland
2 shared publications- Mikko S. Venäläinen
Department of Medical Physics, Turku University Hospital and University of Turku, Turku, Finland
2 shared publications
Latest Publications
- Open Access
- 3 August 2024
- Published by Wiley in British Journal of Haematology
- Vol. 205 (4) , 1460-1468
Radiological follow‐up of osteonecrosis lesions in children and adolescents with Hodgkin lymphoma
Summary: Osteonecrosis (ON) is a common complication of glucocorticoid‐based Hodgkin lymphoma (HL) treatment, but the natural evolution and prognosis of ON lesions remain poorly understood. We describe the radiological evolution of ON lesions identified in a Nordic population‐based cohort of paediatric HL patients. Magnetic resonance images of suspected ON lesions were centrally reviewed to confirm ON diagnosis and grade the ON lesions according to the Niinimäki classification. The study included 202 ON lesions in 46 patients, of which 77 were joint lesions. Follow‐up images were available for 146/202 lesions, with a mean follow‐up time of 28 months. During follow‐up, 71% of the lesions remained stable, 26% improved or resolved, and 3% progressed. A higher ON grade at diagnosis was associated with a lower likelihood of spontaneous resolution. The likelihood for resolution of ON decreased by 50% for each year of added patient age, when adjusted for sex, ON location, and symptoms. Hip ON showed less spontaneous improvement compared with other joints, and the risk for surgery was 13‐fold in hip ON. Grades 3–4 joint ON has the potential to either progress or resolve, warranting follow‐up in patients with severe symptoms. Research on secondary prevention should be directed at grade 3–4 joint ON.
- 3 August 2024
- Published by Wiley in British Journal of Haematology
- Vol. 205 (4) , 1460-1468
Open AccessRadiological follow‐up of osteonecrosis lesions in children and adolescents with Hodgkin lymphoma
Summary: Osteonecrosis (ON) is a common complication of glucocorticoid‐based Hodgkin lymphoma (HL) treatment, but the natural evolution and prognosis of ON lesions remain poorly understood. We describe the radiological evolution of ON lesions identified in a Nordic population‐based cohort of paediatric HL patients. Magnetic resonance images of suspected ON lesions were centrally reviewed to confirm ON diagnosis and grade the ON lesions according to the Niinimäki classification. The study included 202 ON lesions in 46 patients, of which 77 were joint lesions. Follow‐up images were available for 146/202 lesions, with a mean follow‐up time of 28 months. During follow‐up, 71% of the lesions remained stable, 26% improved or resolved, and 3% progressed. A higher ON grade at diagnosis was associated with a lower likelihood of spontaneous resolution. The likelihood for resolution of ON decreased by 50% for each year of added patient age, when adjusted for sex, ON location, and symptoms. Hip ON showed less spontaneous improvement compared with other joints, and the risk for surgery was 13‐fold in hip ON. Grades 3–4 joint ON has the potential to either progress or resolve, warranting follow‐up in patients with severe symptoms. Research on secondary prevention should be directed at grade 3–4 joint ON.
- Open Access
- 10 May 2024
- Published by Wiley in Immunology & Cell Biology
- Vol. 102 (6) , 513-525
Proteomics screening after pediatric allogenic hematopoietic stem cell transplantation reveals an association between increased expression of inhibitory receptor FCRL6 on γδ T cells and cytomegalovirus reactivation
We studied the associations between inflammation‐related proteins in circulation and complications after pediatric allogenic hematopoietic stem cell transplantation (HSCT), to reveal proteomic signatures or individual soluble proteins associated with specific complications after HSCT. We used a proteomics method called Proximity Extension Assay to repeatedly measure 180 different proteins together with clinical variables, cellular immune reconstitution and blood viral copy numbers in 27 children (1–18 years of age) during a 2‐year follow‐up after allogenic HSCT. Protein profile analysis was performed using unsupervised hierarchical clustering and a regression‐based method, while the Bonferroni‐corrected Mann–Whitney U‐test was used for time point–specific comparison of individual proteins against outcome. At 6 months after allogenic HSCT, we could identify a protein profile pattern associated with occurrence of the complications such as chronic graft‐versus‐host disease, viral infections, relapse and death. When protein markers were analyzed separately, the plasma concentration of the inhibitory and cytotoxic T‐cell surface protein FCRL6 (Fc receptor‐like 6) was higher in patients with cytomegalovirus (CMV) viremia [log2‐fold change 1.5 (P = 0.00099), 2.5 (P = 0.00035) and 2.2 (P = 0.045) at time points 6, 12 and 24 months]. Flow cytometry confirmed that FCRL6 expression was higher in innate‐like γδ T cells, indicating that these cells are involved in controlling CMV reactivation in HSCT recipients. In conclusion, the potentially druggable FCRL6 receptor on cytotoxic T cells appears to have a role in controlling CMV viremia after HSCT. Furthermore, our results suggest that system‐level analysis is a useful addition to the studying of single biomarkers in allogenic HSCT.
- 10 May 2024
- Published by Wiley in Immunology & Cell Biology
- Vol. 102 (6) , 513-525
Open AccessProteomics screening after pediatric allogenic hematopoietic stem cell transplantation reveals an association between increased expression of inhibitory receptor FCRL6 on γδ T cells and cytomegalovirus reactivation
We studied the associations between inflammation‐related proteins in circulation and complications after pediatric allogenic hematopoietic stem cell transplantation (HSCT), to reveal proteomic signatures or individual soluble proteins associated with specific complications after HSCT. We used a proteomics method called Proximity Extension Assay to repeatedly measure 180 different proteins together with clinical variables, cellular immune reconstitution and blood viral copy numbers in 27 children (1–18 years of age) during a 2‐year follow‐up after allogenic HSCT. Protein profile analysis was performed using unsupervised hierarchical clustering and a regression‐based method, while the Bonferroni‐corrected Mann–Whitney U‐test was used for time point–specific comparison of individual proteins against outcome. At 6 months after allogenic HSCT, we could identify a protein profile pattern associated with occurrence of the complications such as chronic graft‐versus‐host disease, viral infections, relapse and death. When protein markers were analyzed separately, the plasma concentration of the inhibitory and cytotoxic T‐cell surface protein FCRL6 (Fc receptor‐like 6) was higher in patients with cytomegalovirus (CMV) viremia [log2‐fold change 1.5 (P = 0.00099), 2.5 (P = 0.00035) and 2.2 (P = 0.045) at time points 6, 12 and 24 months]. Flow cytometry confirmed that FCRL6 expression was higher in innate‐like γδ T cells, indicating that these cells are involved in controlling CMV reactivation in HSCT recipients. In conclusion, the potentially druggable FCRL6 receptor on cytotoxic T cells appears to have a role in controlling CMV viremia after HSCT. Furthermore, our results suggest that system‐level analysis is a useful addition to the studying of single biomarkers in allogenic HSCT.
- Open Access
Proteomics screening post pediatric allogeneic hematopoietic stem cell transplantation reveals an association between increased expression of inhibitory receptor FCRL6 on γδ T cells and CMV reactivation
Objective: To study kinetics and associations between inflammation related proteins in circulation after pediatric allogenic hematopoietic stem cell transplantation (HSCT) to reveal proteomic signatures or individual soluble proteins associated with specific complications post HSCT. Methods: We used a proteomics method called Proximity Extension Assay to repeatedly measure 180 different proteins together with clinical variables, cellular immune reconstitution, and blood viral copy numbers in 27 children aged 1-18 years during a two-year follow up after allogenic HSCT. Protein profile analysis was done using unsupervised hierarchical clustering and a regression-based method, while Bonferroni-corrected Mann-Whitney U test was used for time point specific comparison of individual proteins against outcome. Results: At 6 months after allogenic HSCT, we could identify a protein profile pattern associated with occurrence of the complications chronic graft-versus-host disease, viral infections, relapse, and death. When protein markers were analyzed separately, the plasma concentration of the inhibitory and cytotoxic T cell surface protein FCRL6 (Fc receptor-like 6) was higher in patients with CMV viremia (log2-fold change 1.5 (p0.00099), 2.5 (p=0.00035) and 2.2 (p=0.045) at time points 6, 12 and 24 months). Flow cytometry confirmed that FCRL6 expression was higher in innate-like γδ T cells, indicating that these cells have a role in controlling CMV reactivation in HSCT recipients. Conclusions: The potentially druggable FCRL6 receptor on cytotoxic T cells appears to have a role in controlling CMV viremia post-HSCT. Our results suggest that system level analysis is a useful addition to the studying of single biomarkers in allogeneic HSCT.
Open AccessProteomics screening post pediatric allogeneic hematopoietic stem cell transplantation reveals an association between increased expression of inhibitory receptor FCRL6 on γδ T cells and CMV reactivation
Objective: To study kinetics and associations between inflammation related proteins in circulation after pediatric allogenic hematopoietic stem cell transplantation (HSCT) to reveal proteomic signatures or individual soluble proteins associated with specific complications post HSCT. Methods: We used a proteomics method called Proximity Extension Assay to repeatedly measure 180 different proteins together with clinical variables, cellular immune reconstitution, and blood viral copy numbers in 27 children aged 1-18 years during a two-year follow up after allogenic HSCT. Protein profile analysis was done using unsupervised hierarchical clustering and a regression-based method, while Bonferroni-corrected Mann-Whitney U test was used for time point specific comparison of individual proteins against outcome. Results: At 6 months after allogenic HSCT, we could identify a protein profile pattern associated with occurrence of the complications chronic graft-versus-host disease, viral infections, relapse, and death. When protein markers were analyzed separately, the plasma concentration of the inhibitory and cytotoxic T cell surface protein FCRL6 (Fc receptor-like 6) was higher in patients with CMV viremia (log2-fold change 1.5 (p0.00099), 2.5 (p=0.00035) and 2.2 (p=0.045) at time points 6, 12 and 24 months). Flow cytometry confirmed that FCRL6 expression was higher in innate-like γδ T cells, indicating that these cells have a role in controlling CMV reactivation in HSCT recipients. Conclusions: The potentially druggable FCRL6 receptor on cytotoxic T cells appears to have a role in controlling CMV viremia post-HSCT. Our results suggest that system level analysis is a useful addition to the studying of single biomarkers in allogeneic HSCT.
- Open Access
Genome-Wide Association Meta-Analysis of Single-Nucleotide Polymorphisms and Symptomatic Venous Thromboembolism during Therapy for Acute Lymphoblastic Leukemia and Lymphoma in Caucasian Children
Symptomatic venous thromboembolism (VTE) occurs in five percent of children treated for acute lymphoblastic leukemia (ALL), but whether a genetic predisposition exists across different ALL treatment regimens has not been well studied. Methods: We undertook a genome-wide association study (GWAS) meta-analysis for VTE in consecutively treated children in the Nordic/Baltic acute lymphoblastic leukemia 2008 (ALL2008) cohort and the Australian Evaluation of Risk of ALL Treatment-Related Side-Effects (ERASE) cohort. A total of 92 cases and 1481 controls of European ancestry were included. Results: No SNPs reached genome-wide significance (p < 5 × 10−8) in either cohort. Among the top 34 single-nucleotide polymorphisms (SNPs) (p < 1 × 10−6), two loci had concordant effects in both cohorts: ALOX15B (rs1804772) (MAF: 1%; p = 3.95 × 10−7) that influences arachidonic acid metabolism and thus platelet aggregation, and KALRN (rs570684) (MAF: 1%; p = 4.34 × 10−7) that has been previously associated with risk of ischemic stroke, atherosclerosis, and early-onset coronary artery disease. Conclusion: This represents the largest GWAS meta-analysis conducted to date associating SNPs to VTE in children and adolescents treated on childhood ALL protocols. Validation of these findings is needed and may then lead to patient stratification for VTE preventive interventions. As VTE hemostasis involves multiple pathways, a more powerful GWAS is needed to detect combination of variants associated with VTE.
Open AccessGenome-Wide Association Meta-Analysis of Single-Nucleotide Polymorphisms and Symptomatic Venous Thromboembolism during Therapy for Acute Lymphoblastic Leukemia and Lymphoma in Caucasian Children
Symptomatic venous thromboembolism (VTE) occurs in five percent of children treated for acute lymphoblastic leukemia (ALL), but whether a genetic predisposition exists across different ALL treatment regimens has not been well studied. Methods: We undertook a genome-wide association study (GWAS) meta-analysis for VTE in consecutively treated children in the Nordic/Baltic acute lymphoblastic leukemia 2008 (ALL2008) cohort and the Australian Evaluation of Risk of ALL Treatment-Related Side-Effects (ERASE) cohort. A total of 92 cases and 1481 controls of European ancestry were included. Results: No SNPs reached genome-wide significance (p < 5 × 10−8) in either cohort. Among the top 34 single-nucleotide polymorphisms (SNPs) (p < 1 × 10−6), two loci had concordant effects in both cohorts: ALOX15B (rs1804772) (MAF: 1%; p = 3.95 × 10−7) that influences arachidonic acid metabolism and thus platelet aggregation, and KALRN (rs570684) (MAF: 1%; p = 4.34 × 10−7) that has been previously associated with risk of ischemic stroke, atherosclerosis, and early-onset coronary artery disease. Conclusion: This represents the largest GWAS meta-analysis conducted to date associating SNPs to VTE in children and adolescents treated on childhood ALL protocols. Validation of these findings is needed and may then lead to patient stratification for VTE preventive interventions. As VTE hemostasis involves multiple pathways, a more powerful GWAS is needed to detect combination of variants associated with VTE.
- 13 March 2020
- Published by Taylor & Francis in Pediatric Hematology and Oncology
- Vol. 37 (5) , 355-364
Acute toxicity and outcome among pediatric allogeneic hematopoietic transplant patients conditioned with treosulfan-based regimens
Treosulfan-based regimens constitute a feasible and increasingly used, but still myeloablative, conditioning in pediatric allogeneic hematopoietic stem cell transplantation (HSCT). We retrospectively analyzed the acute toxicity and outcome of all consecutive (2004–2015) pediatric HSCT patients prepared for HSCT with treosulfan in a single-center setting. We included HSCTs performed for both nonmalignant (n = 23) and malignant diseases (n = 11). The controls were patients with nonmalignant diseases or hematological malignancies conditioned with cyclophosphamide (Cy)-total body irradiation (TBI)-based (39 patients) or busulfan-based regimens (11 patients). The major toxicities of the treosulfan-based regimens were limited to oral mucosa and skin. 50% of the patients needed IV morphine for severe mucositis compared to 31% in patients conditioned with Cy-TBI (P = 0.02). Other toxicities were rare. The disease-free survival (DFS) of patients transplanted for nonmalignant disorders was 88.9 ± 7.5% at 2 years. The event-free survival (EFS) at 2 years in this small cohort for those with a malignant disease and a treosulfan-based conditioning was 54.5 ± 1.5%. We conclude that a treosulfan-based conditioning regimen gives excellent DFS in pediatric HSCT performed for a nonmalignant disorder but with substantial mucosal toxicity. In a malignant disorder a treosulfan-based regimen looks promising but larger, preferably randomized, studies are needed to prove efficacy.
- 13 March 2020
- Published by Taylor & Francis in Pediatric Hematology and Oncology
- Vol. 37 (5) , 355-364
Acute toxicity and outcome among pediatric allogeneic hematopoietic transplant patients conditioned with treosulfan-based regimens
Treosulfan-based regimens constitute a feasible and increasingly used, but still myeloablative, conditioning in pediatric allogeneic hematopoietic stem cell transplantation (HSCT). We retrospectively analyzed the acute toxicity and outcome of all consecutive (2004–2015) pediatric HSCT patients prepared for HSCT with treosulfan in a single-center setting. We included HSCTs performed for both nonmalignant (n = 23) and malignant diseases (n = 11). The controls were patients with nonmalignant diseases or hematological malignancies conditioned with cyclophosphamide (Cy)-total body irradiation (TBI)-based (39 patients) or busulfan-based regimens (11 patients). The major toxicities of the treosulfan-based regimens were limited to oral mucosa and skin. 50% of the patients needed IV morphine for severe mucositis compared to 31% in patients conditioned with Cy-TBI (P = 0.02). Other toxicities were rare. The disease-free survival (DFS) of patients transplanted for nonmalignant disorders was 88.9 ± 7.5% at 2 years. The event-free survival (EFS) at 2 years in this small cohort for those with a malignant disease and a treosulfan-based conditioning was 54.5 ± 1.5%. We conclude that a treosulfan-based conditioning regimen gives excellent DFS in pediatric HSCT performed for a nonmalignant disorder but with substantial mucosal toxicity. In a malignant disorder a treosulfan-based regimen looks promising but larger, preferably randomized, studies are needed to prove efficacy.
- 21 November 2014
- Published by Wiley in Pediatric Blood & Cancer
- Vol. 62 (3) , 522-528
Impact of very early CD4+/CD8+ T cell counts on the occurrence of acute graft‐versus‐host disease and NK cell counts on outcome after pediatric allogeneic hematopoietic stem cell transplantation
Background: Increasing evidence suggests that early and rapid lymphocyte recovery following allogeneic hematopoietic stem cell transplantation (HSCT) is associated with better survival.Procedure: We retrospectively analyzed very early lymphocyte subset counts following transplantation from our 5‐year pediatric allogeneic HSCT material to find clinically relevant associations with post transplant outcome, and the major complication of HSCT, acute graft‐versus‐host disease (aGVHD). We analyzed HSCTs performed due to acute leukemias and lymphomas from matched unrelated donors (MUD, n = 33), unrelated cord blood (UCB, n = 9) and matched sibling donors (MSD, n = 17).Results: Patients with grafts from MUDs and grade II‐IV aGVHD) had higher (median 2.1 compared to 0.3, PP = 0.004) first measurable CD4+/CD8+ T cell ratio, compared to patients with no or grade I aGVHD, respectively. At day +32 after HSCT patients with MUDs and significant aGVHD had higher levels of both CD4+ and CD8+ T cell subsets. Low (below median 120/µL) versus high natural killer (NK) cell counts at day +32 were associated with 3‐year event‐free survival of 27.4 +/− 9.0% versus 82.4 +/− 6.4% (P < 0.0001), cumulative transplant‐related mortality of 44.7 +/− 12.2% versus 3.0 +/− 3.0% (P < 0.001) and cumulative relapse incidence of 50.4 +/− 12.2% versus 15.0 +/− 6.2% (P = 0.019), respectively.Conclusions: We conclude that early lymphocyte subset counts following allogeneic HSCT have an association with aGVHD and post transplant outcome. Pediatr Blood Cancer 2015;62:522–528.
- 21 November 2014
- Published by Wiley in Pediatric Blood & Cancer
- Vol. 62 (3) , 522-528
Impact of very early CD4+/CD8+ T cell counts on the occurrence of acute graft‐versus‐host disease and NK cell counts on outcome after pediatric allogeneic hematopoietic stem cell transplantation
Background: Increasing evidence suggests that early and rapid lymphocyte recovery following allogeneic hematopoietic stem cell transplantation (HSCT) is associated with better survival.Procedure: We retrospectively analyzed very early lymphocyte subset counts following transplantation from our 5‐year pediatric allogeneic HSCT material to find clinically relevant associations with post transplant outcome, and the major complication of HSCT, acute graft‐versus‐host disease (aGVHD). We analyzed HSCTs performed due to acute leukemias and lymphomas from matched unrelated donors (MUD, n = 33), unrelated cord blood (UCB, n = 9) and matched sibling donors (MSD, n = 17).Results: Patients with grafts from MUDs and grade II‐IV aGVHD) had higher (median 2.1 compared to 0.3, PP = 0.004) first measurable CD4+/CD8+ T cell ratio, compared to patients with no or grade I aGVHD, respectively. At day +32 after HSCT patients with MUDs and significant aGVHD had higher levels of both CD4+ and CD8+ T cell subsets. Low (below median 120/µL) versus high natural killer (NK) cell counts at day +32 were associated with 3‐year event‐free survival of 27.4 +/− 9.0% versus 82.4 +/− 6.4% (P < 0.0001), cumulative transplant‐related mortality of 44.7 +/− 12.2% versus 3.0 +/− 3.0% (P < 0.001) and cumulative relapse incidence of 50.4 +/− 12.2% versus 15.0 +/− 6.2% (P = 0.019), respectively.Conclusions: We conclude that early lymphocyte subset counts following allogeneic HSCT have an association with aGVHD and post transplant outcome. Pediatr Blood Cancer 2015;62:522–528.
- 1 January 2014
- Vol. 130 (20) , 2050-9
[Solid tumors in children].
A quarter of cancers diagnosed in those under 18 years of age are leukemias, another quarter being tumors of the central nervous system. The remaining cancers are solid tumors occurring elswehere in the body, most commonly lymphomas, soft tissue and bone sarcomas, neuroblastomas and Wilms tumors. In almost all cases, the treatment of these solid tumors consists of combinations of surgery, cytotoxic drugs and radiotherapy. Although the prognoses have improved, they exhibit variation even within tumor groups. New targeted therapies are being developed, but for the time being they do not have any significant role.
- 1 January 2014
- Vol. 130 (20) , 2050-9
[Solid tumors in children].
A quarter of cancers diagnosed in those under 18 years of age are leukemias, another quarter being tumors of the central nervous system. The remaining cancers are solid tumors occurring elswehere in the body, most commonly lymphomas, soft tissue and bone sarcomas, neuroblastomas and Wilms tumors. In almost all cases, the treatment of these solid tumors consists of combinations of surgery, cytotoxic drugs and radiotherapy. Although the prognoses have improved, they exhibit variation even within tumor groups. New targeted therapies are being developed, but for the time being they do not have any significant role.